[1] RUGGIERO R J, LIKIS F E. Estrogen:physiology, pharmacology, and formulations for replacement therapy[J]. J Midwifery Womens Health, 2002, 47(3):130-138.
[2] KNOWLTON A A, LEE A R. Estrogen and the cardiovascular system[J]. Pharmacol Ther, 2012, 135(1):54-70.
[3] WOOLLEY C S. Effects of estrogen in the CNS[J]. Curr Opin Neurobiol, 1999, 9(3):349-354.
[4] PATEL S, HOMAEI A, RAJU A B, et al. Estrogen:the necessary evil for human health, and ways to tame it[J]. Biomed Pharmacother, 2018, 102:403-411.
[5] JIA M, DAHLMAN-WRIGHT K, GUSTAFSSON J Å. Estrogen receptor alpha and beta in health and disease[J]. Best Pract Res Clin Endocrinol Metab, 2015, 29(4):557-568.
[6] CARMECI C, THOMPSON D A, RING H Z, et al. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer[J]. Genomics, 1997, 45(3):607-617.
[7] OLDE B,LEEB-LUNDBERG L M. GPR30/GPER1:searching for a role in estrogen physiology[J]. Trends Endocrinol Metab, 2009, 20(8):409-416.
[8] PROSSNITZ E R,BARTON M. The G-protein-coupled estrogen receptor GPER in health and disease[J]. Nat Rev Endocrinol, 2011, 7(12):715-726.
[9] BOON W C,CHOW J D Y,SIMPSON E R. The multiple roles of estrogens and the enzyme aromatase[J]. Prog Brain Res, 2010, 181:209-232.
[10] FUENTES N, SILVEYRA P. Estrogen receptor signaling mechanisms[J]. Adv Protein Chem Struct Biol, 2019, 116:135-170.
[11] JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
[12] QIN J, LIU M, DING Q S, et al. The direct effect of estrogen on cell viability and apoptosis in human gastric cancer cells[J]. Mol Cell Biochem, 2014, 395(1/2):99-107.
[13] RYU W S, KIM J H, JANG Y J, et al. Expression of estrogen receptors in gastric cancer and their clinical significance[J]. J Surg Oncol, 2012, 106(4):456-461.
[14] YI J H, DO I G, JANG J, et al. Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer[J]. Sci Rep, 2014, 4:7592.
[15] TIAN S, ZHAN N, LI R X, et al. Downregulation of G protein-coupled estrogen receptor (GPER) is associated with reduced prognosis in patients with gastric cancer[J]. Med Sci Monit, 2019, 25:3115-3126.
[16] LEE S J,KIM T W,PARK G L,et al. G protein-coupled estrogen receptor-1 agonist induces chemotherapeutic effect via ER stress signaling in gastric cancer[J]. BMB Rep, 2019, 52(11):647-652.
[17] FATTAHI S, AMJADI-MOHEB F, TABARIPOUR R, et al. PI3K/AKT/mTOR signaling in gastric cancer:Epigenetics and beyond[J]. Life Sci, 2020, 262:118513.
[18] PENG X R, SHI J Y, ZHAO Z P, et al. Emetine, a small molecule natural product,displays potent anti-gastric cancer activity via regulation of multiple signaling pathways[J]. Cancer Chemother Pharmacol, 2023, 91(4):303-315.
[19] WANG Y, CHU F H, LIN J, et al. Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification[J]. J Ethnopharmacol, 2021, 279:114399.
[20] BARZI A,LENZ A M,LABONTE M J,et al. Molecular pathways:Estrogen pathway in colorectal cancer[J]. Clin Cancer Res,2013,19(21):5842-5848.
[21] GE H, LIANG C J, LI Z X, et al. DcR3 induces proliferation, migration, invasion, and EMT in gastric cancer cells via the PI3K/AKT/GSK-3β/β-catenin signaling pathway[J]. Onco Targets Ther, 2018, 11:4177-4187.
[22] XU E, XIA X F, JIANG C Y, et al. GPER1 silencing suppresses the proliferation,migration,and invasion of gastric cancer cells by inhibiting PI3K/AKT-mediated EMT[J]. Front Cell Dev Biol, 2020, 8:591239.
[23] XU H W,CHEN Y R,OUYANG S S,et al. HOTAIR plays an oncogenic role in gastric cancer through microRNA and SNP[J]. Neoplasma, 2021, 68(3):465-471.
[24] KANG S,PARK M,CHO J Y,et al. Tumorigenic mechanisms of estrogen and Helicobacter pylori cytotoxin-associated gene A in estrogen receptor α-positive diffuse-type gastric adenocarcinoma[J]. Gastric Cancer, 2022, 25(4):678-696.
[25] KIM H S,KIM M H,JEONG M,et al. EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells[J]. Anticancer Res, 2004, 24(2B):747-753.
[26] LEI Y,CHEN X,MO J L,et al. Vascular endothelial growth factor promotes transdifferentiation of astrocytes into neurons via activation of the MAPK/Erk-Pax6 signal pathway[J]. Glia, 2023, 71(7):1648-1666.
[27] GUO Y J, PAN W W, LIU S B, et al. ERK/MAPK signalling pathway and tumorigenesis[J]. Exp Ther Med, 2020, 19(3):1997-2007.
[28] DOS SANTOS E G, DIEUDONNE M N, PECQUERY R, et al. Rapid nongenomic E2 effects on p42/p44 MAPK,activator protein-1,and cAMP response element binding protein in rat white adipocytes[J]. Endocrinology, 2002, 143(3):930-940.
[29] UR RAHMAN M S,CAO J. Estrogen receptors in gastric cancer:advances and perspectives[J]. World J Gastroenterol, 2016, 22(8):2475-2482.
[30] WANG Y, ZHENG L X, SHANG W J, et al. Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer[J]. Cell Death Differ, 2022, 29(11):2190-2202.
[31] AKHAVANFAR R, SHAFAGH S G, MOHAMMADPOUR B, et al. A comprehensive insight into the correlation between ncRNAs and the Wnt/β-catenin signalling pathway in gastric cancer pathogenesis[J]. Cell Commun Signal, 2023, 21(1):166.
[32] ZHANG L, XIONG W Q, XIONG Y, et al. 17β-Estradiol promotes vascular endothelial growth factor expression via the Wnt/β-catenin pathway during the pathogenesis of endometriosis[J]. Mol Hum Reprod, 2016, 22(7):526-535.
[33] YU Z Y, JIANG X Y, QIN L, et al. Correction:a novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination[J]. Oncogene, 2021, 40(14):2622-2623.
[34] ABANCENS M,HARVEY B J,MCBRYAN J. GPER agonist G1 prevents wnt-induced JUN upregulation in HT29 colorectal cancer cells[J]. Int J Mol Sci, 2022, 23(20):12581.
[35] SOKOLOVA O, NAUMANN M. NF-κB signaling in gastric cancer[J]. Toxins, 2017, 9(4):119.
[36] LI S N,KHOI P N,YIN H,et al. Sulforaphane suppresses the nicotine-induced expression of the matrix metalloproteinase-9 via inhibiting ROS-mediated AP-1 and NF-κB signaling in human gastric cancer cells[J]. Int J Mol Sci, 2022, 23(9):5172.
[37] HAZAFA A, REHMAN K U, JAHAN N, et al. The role of polyphenol (flavonoids) compounds in the treatment of cancer cells[J]. Nutr Cancer, 2020, 72(3):386-397.
[38] YANG X F,ZHANG J Q,MA J,et al. GPER governs the immune infiltration of gastric cancer and activates the NF-κB/ROS/Apoptosis pathway in gastric mucosal epithelium[J]. Int Immunopharmacol, 2023, 122:110641.
[39] MORGAN M J,LIU Z G. Crosstalk of reactive oxygen species and NF-κB signaling[J]. Cell Res, 2011, 21(1):103-115. |
